Get the Stockscreener App
1.46
0.00%
0.00
After Hours:
1.48
0.02
+1.37%
NanoViricides Inc stock is traded at $1.46, with a volume of 209.02K.
It is up +0.00% in the last 24 hours and up +44.55% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.46
Open:
$1.5
24h Volume:
209.02K
Relative Volume:
0.80
Market Cap:
$31.53M
Revenue:
-
Net Income/Loss:
$-8.32M
P/E Ratio:
-3.0316
EPS:
-0.4816
Net Cash Flow:
$-7.43M
1W Performance:
+19.67%
1M Performance:
+44.55%
6M Performance:
-23.16%
1Y Performance:
+15.77%
1-Day Range:
$1.43
$1.58
1-Week Range:
$1.19
$1.58
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.46 | 31.53M | 0 | -8.32M | -7.43M | -0.4816 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference - Oil & Gas 360
NanoViricides to attend D Boral Capital Conference - Proactive financial news
NanoViricides management offers investor meetings in New York May 7 - Stock Titan
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - Yahoo Finance
NanoViricides’ NV-387 Receives FDA Orphan Drug Designation for Measles Treatment - citybuzz -
NanoViricdes Surges on Winning ODD Status - Baystreet.ca
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - Lelezard
NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment - Yahoo Finance
FDA orphan tag gives NanoViricides measles drug tax credits, fee waiver - Stock Titan
Is NanoViricides (NNVC) stock forming a clear pattern | Q1 2026: Profit Exceeds ViewsDividend Safety - Newser
NNVC Forecast, Price Target & Analyst Ratings | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NNVC (NanoViricides Inc.) beats Q1 2026 EPS estimates by 23 percent, but posts a slight post-earnings share decline. - Cổng thông tin điện tử tỉnh Tây Ninh
NNVC NanoViricides exceeds Q1 2026 EPS estimates by 23 percent, but shares drop 4.89 percent on zero quarterly revenue.Trading Community - UBND thành phố Hải Phòng
NanoViricides says NV-387 could address measles outbreaks as cases rise globally - Yahoo Finance
Deadly Measles Cases Accentuate the Need for a - One News Page
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC Tomorrow - AOL.com
Profit Recap: Can NanoViricides Inc continue delivering strong returns2026 Volatility Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387ICYMI - Proactive financial news
Macro Review: Should I hold or sell GMREPRA now2026 Spike Watch & Community Consensus Stock Picks - baoquankhu1.vn
Weekly Earnings: Is NanoViricides Inc subject to activist investor interestTake Profit & Real-Time Buy Signal Notifications - baoquankhu1.vn
Aug Summary: Is NanoViricides Inc undervalued by DCF analysisWeekly Gains Report & Stock Timing and Entry Methods - baoquankhu1.vn
NanoViricides files for Rare Pediatric Disease Designation for Measles Drug - Proactive financial news
Growth Value: Can NanoViricides Inc stock double in the next year2026 Technical Overview & Short-Term Trading Alerts - baoquankhu1.vn
Can NanoViricides (NNVC) Stock Go Higher | Price at $1.15, Up 6.48%Day Trade - Newser
Activity Recap: Is NanoViricides Inc forming a bullish divergencePortfolio Value Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
NanoViricides Seeks Rare Pediatric Disease Designation for Measles Treatment Candidate - citybuzz -
Measles Rare Pediatric Disease Drug Designation Application File - GuruFocus
NanoViricides seeks rare pediatric disease status for measles drug NV-387 - Yahoo Finance
About Us - FinancialContent
Aug Shorts: Is NanoViricides Inc forming a breakout pattern2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
NNVC Stock Analysis: NanoViricides Inc Biotech Stock Post 2.55% Daily Dip At $0.93 Level - Xã Vĩnh Công
Can NanoViricides (NNVC) Stock Recover Now | Price at $0.93, Down 2.11%Social Investment Platform - Newser
Small caps wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X… - proactiveinvestors.co.uk
NanoViricides to Begin Phase II MPox Clinical Trial in Democratic Republic of Congo - citybuzz -
Small cap wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X… - Proactive financial news
NanoViricides to begin Phase II trial of MPox treatment in Congo - Proactive financial news
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides - ACCESS Newswire
Monkeypox drug trial cleared in Congo as NanoViricides readies dosing - Stock Titan
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):